ЗОЛЕНДРОВІСТА

ਉਤਪਾਦ ਝਲਕ

About ЗОЛЕНДРОВІСТА

ЗОЛЕНДРОВІСТА is a medication containing the active ingredient Zoledronic acid, a bisphosphonate used in the treatment of bone diseases. It is primarily prescribed for the management of bone metastases in patients with malignancies, such as breast cancer, lung cancer, and multiple myeloma, as well as for the treatment of osteoporosis in postmenopausal women and men.

Key Benefits & Uses

• Treatment of bone metastases in patients with malignancies, including breast cancer, lung cancer, and multiple myeloma
• Treatment of osteoporosis in postmenopausal women and men
• Prevention of skeletal events in patients with bone metastases

Active Ingredient & Action

Zoledronic acid works by inhibiting osteoclast-mediated bone resorption, thereby reducing bone turnover and increasing bone density. It binds to hydroxyapatite in bone, making it resistant to bone resorption and promoting bone mineralization.

Important Notes

ЗОЛЕНДРОВІСТА should be administered under the guidance of a healthcare professional. It is essential to follow the recommended dosage and treatment schedule to minimize the risk of adverse effects, such as renal impairment, hypocalcemia, and flu-like symptoms. Patients with renal impairment or a history of hypersensitivity reactions to Zoledronic acid should be closely monitored during treatment.